[Skip to Navigation]
August 1949


Arch Derm Syphilol. 1949;60(2):196-205. doi:10.1001/archderm.1949.01530020064010

DURING the past twenty-five years bismuth has been employed extensively in the treatment of disease. It has proved an effective agent not only in syphilotherapy but also as an empiric remedy in a number of varied dermatoses, in the majority of which the etiologic basis has not been clearly established. Until recently, salts of bismuth have been administered by intramuscular injection and the results of oral administration of the drug have been disappointing, not because of a poor therapeutic response but because of gastrointestinal intolerance. Sodium bismuth triglycollamate (bistrimate®),1 one of the newer bismuth salts available for oral administration, gives promise of being therapeutically effective without producing a high percentage of severe reactions. Gross and Wright2 have reported satisfactory results from the use of this agent in the treatment of syphilis and a number of dermatoses known to be responsive to bismuth therapy. Sawicky3 has

Add or change institution